menu

IMpower010 Study: Targeted Therapy & Highlights from ESMO 2021 on NSCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

IMpower010 Study: Targeted Therapy & Highlights from ESMO 2021 on NSCLC

ReachMD Image
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Could a new standard of treatment be on the horizon for patients with HER2 mutated NSCLC? Dr. Edward Garon, a Thoracic Medical Oncologist at UCLA Health, shares key takeaways on non-small cell lung cancer from the ESMO 2021 Congress.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Could a new standard of treatment be on the horizon for patients with HER2 mutated NSCLC? Dr. Edward Garon, a Thoracic Medical Oncologist at UCLA Health, shares key takeaways on non-small cell lung cancer from the ESMO 2021 Congress.

Facebook Comments

Schedule27 Nov 2021
Webpack App